A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee

• Symptomatic disease due to osteoarthritis, defined as a WOMAC Pain score ≥ 8 (worst possible = 20)

• Focused Analgesia Selection Test will be used to determine whether patients can report pain with sufficient consistency to enter the clinical trial

• Males and females between 45 and 85 years of age, inclusive

• Kellgren-Lawrence grading of 2 or 3 within the last 6 months

• Stable analgesic regimen during the 4 weeks prior to enrollment

• In the judgment of the Investigator, acceptable general medical condition

• Life expectancy \>6 months

• Male and female participants who are heterosexually active and not surgically sterile must agree to use effective contraception, including abstinence, for the duration of the study

• Have suitable knee joint anatomy for intra-articular injection

⁃ Willing and able to return for the follow-up (FU) visits

⁃ Able to read and understand study instructions, and willing and able to comply with all study procedures